O Orexo AB
O
Gesloten
19.5 -0.1
Overzicht
Wijziging aandelenprijs
24u
Min
19.32
Max
19.76
Inkomsten | 41M -75M |
|---|---|
Verkoop | 1.7M 5M |
EPS | -3.812 |
Winstmarge | -1,500 |
Werknemers | 65 |
EBITDA | 206M -66M |
Volgende Winsten | 16 jul 2026 |
|---|
Marktkapitalisatie | -53M 647M |
|---|---|
Vorige openingsprijs | 19.6 |
Vorige sluitingsprijs | 19.5 |
Orexo AB Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Orexo AB Prognose
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
